Pain Quality Predicts Lidocaine Analgesia among Patients with Suspected Neuropathic Pain

被引:17
|
作者
Carroll, Ian R. [1 ]
Younger, Jared W. [1 ]
Mackey, Sean C. [1 ]
机构
[1] Stanford Univ, Sch Med, Palo Alto, CA 94040 USA
关键词
Lidocaine; Pain; Neuropathic Pain; Pain Quality; Sodium Channel Blockade; Intravenous Lidocaine; McGill Pain Questionnaire; Factor Analysis;
D O I
10.1111/j.1526-4637.2010.00807.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective. Oral sodium channel blockers have shown mixed results in randomized controlled trials despite the known importance of sodium channels in generating pain. We hypothesized that differing baseline pain qualities (e.g. "stabbing" vs "dull") might define specific subgroups responsive to intravenous (IV) lidocaine-a potent sodium channel blocker. Design. A prospective cohort study of 71 patient with chronic pain suspected of being neuropathic were recruited between January 2003 and July 2007 and underwent lidocaine infusions at Stanford University Hospital in a single-blind nonrandomized fashion. Baseline sensory pain qualities were measured with the Short-Form McGill Pain Questionnaire (SF-MPQ). Pain intensity was measured with a visual analog scale (VAS). Results. Factor analysis demonstrated two underlying pain quality factors among SF-MPQ sensory items: a heavy pain and a stabbing pain. Baseline heavy pain quality, but not stabbing quality predicted subsequent relief of pain intensity in response to lidocaine. In contrast, these factors did not predict divergent analgesic responses to placebo infusions. In response to each 1 mcg/mL increase in lidocaine plasma level, patients with high heavy pain quality drop their VAS 0.24 (95% CI 0.05-0.43) more points than those with low heavy pain quality (P < 0.013). Conclusions. "Heavy" pain quality may indentify patients with enhanced lidocaine responsiveness. Pain quality may identify subgroups among patients with suspected neuropathic pain responsive to IV lidocaine. Further investigation is warranted to validate and extend these findings.
引用
收藏
页码:617 / 621
页数:5
相关论文
共 50 条
  • [1] Symptoms and signs in patients with suspected neuropathic pain
    Rasmussen, PV
    Sindrup, SH
    Jensen, TS
    Bach, FW
    PAIN, 2004, 110 (1-2) : 461 - 469
  • [2] Continual systemic infusion of lidocaine provides analgesia in an animal model of neuropathic pain
    Smith, LJ
    Shih, A
    Miletic, G
    Miletic, V
    PAIN, 2002, 97 (03) : 267 - 273
  • [3] ANALGESIA Inhibiting neuropathic pain
    Harrison, Charlotte
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (03) : 176 - 176
  • [4] Systemic lidocaine for neuropathic pain relief
    Mao, JR
    Chen, LL
    PAIN, 2000, 87 (01) : 7 - 17
  • [5] Systemic lidocaine or mexiletine for neuropathic pain
    Ebell, Mark H.
    AMERICAN FAMILY PHYSICIAN, 2006, 74 (01) : 79 - 79
  • [6] Topical Lidocaine for Localized Neuropathic Pain
    Lattanzi, Simona
    Provinciali, Leandro
    ARCHIVES OF NEUROSCIENCE, 2016, 3 (01)
  • [7] Parenteral Lidocaine for Neuropathic Pain #180
    Thomas, Jay
    JOURNAL OF PALLIATIVE MEDICINE, 2009, 12 (02) : 188 - 189
  • [8] Topical lidocaine for neuropathic pain in adults
    Derry, Sheena
    Wiffen, Philip J.
    Moore, R. Andrew
    Quinlan, Jane
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (07):
  • [9] Neurosensory findings after intravenous lidocaine in patients with neuropathic pain
    Ridgeway, B
    Wallace, M
    Gerayli, A
    Dunn, J
    Yaksh, T
    ANESTHESIOLOGY, 1997, 87 (03) : A758 - A758
  • [10] Pain catastrophizing predicts poor response to topical analgesics in patients with neuropathic pain
    Mankovsky, Tsipora
    Lynch, Mary E.
    Clark, A. J.
    Sawynok, J.
    Sullivan, Michael J. L.
    PAIN RESEARCH & MANAGEMENT, 2012, 17 (01): : 10 - 14